Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

Scroll down and select country
MEBO TMAU TESTING CURRENTLY SUSPENDED INDEFINITELY

MEBO - UBIOME study 2018

'PRESS RELEASE'

NCT03582826
ClinicalTrials.gov

MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

NO LONGER RECRUITING

Participation info : LINK English

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact info@meboresearch.org

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts

MEBO TMAU Videos

Petitions

TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

London TMAU meeting with Prof Liz Shephard
19th Oct 11am - 1pm
St Mary's Hospital
Praed St, Paddington
London W2 1NY
click to read more
more details : karen.james@meboresearch.org

MEBO Research Clinical Trials

Click here to read details of the MEBO Clinical Trials
NCT03582826 - Ongoing not recruiting
Microbial Basis of Systemic Malodor and PATM Conditions (PATM)
United States 2018 - ongoing

NCT02683876 - Completed
Exploratory Study of Relationships Between Malodor and Urine Metabolomics
Canada and United States 2016 - ongoing

NCT03451994 - Completed
Exploratory Study of Volatile Organic Compounds in Alveolar Breath
United Kingdom and United States 2013 - ongoing

NCT02692495 - Completed
Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis
United Kingdom 2009 - 2012

Monday, March 21, 2011

New FMO3 paper involving Dr John Cashman

Readers will know that Dr John Cashman of HBRI in San Diego has been at the forefront of FMO3/TMAU research for over a decade now, although overall there is little FMO3 research in general. Nowadays there is very little research seeming to be published on the subject other than by Dr Cashman.

For this new paper he has teamed up with a Japanese researcher who also has a history in TMAU/FMO3 research and with whom Dr Cashman has worked before. Reading the Abstract, this study seems to have been to largely find out the degree of FMO3 activity in childhood and involved testing 77 children ? The conclusions seem to be that trimethylamine in children seems to largely carried out by FMO3 and no part is played by FMO1 or FMO5. It needs clarifying, but it seems to suggest that children with just one 'flawed' copy of an FMO3 gene appeared to have variations in FMO3 development, at least in childhood ?

Developmental variations in metabolic capacity of flavin-containing mono-oxygenase 3 in childhood.
Shimizu M, Denton T, Kozono M, Cashman JR, Leeder JS, Yamazaki H.

Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan Human BioMolecular Research Institute, San Diego, CA 92121 Children's Mercy Hospital, Kansas City, MO 64108, USA.

Abstract
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • The function of the human flavin-containing mono-oxygenase (FMO) has been shown to have large inter-individual variation related to trimethylaminuria. WHAT THIS STUDY ADDS • The study suggests that a developmental variation in functional metabolic capacity of FMO3 is occurring in childhood on the basis of in vivo phenotyping tests and in vitro liver microsomal determinations. AIM The aim of this study was to investigate intra- and inter-individual variations of functional metabolic capacity of flavin-containing mono-oxygenase (FMO) during childhood using trimethylamine N-oxygenation as a probe reaction. METHODS Trimethylamine N-oxygenation functional activity and presence of FMO1 (fetal form), FMO3 (adult form), and FMO5 (endogenous form) were immunochemically determined and compared in human liver microsomes obtained from children at various ages. As a control, the same parameters were studied with recombinant FMO1, FMO3 and FMO5 proteins as enzyme sources. Developmental variation in functional metabolic capacity of FMO was estimated by measuring urinary trimethylamine and its N-oxide in several individuals at different ages and in a group of 77 subjects in childhood. RESULTS There was a significant correlation between trimethylamine N-oxygenation functional activity and FMO3 expression levels in human liver microsomes (r= 0.71, P < 0.05, n= 9). Trimethylamine N-oxygenation was catalyzed largely by FMO3 and not by FMO1 or FMO5. On the basis of analysis of intra-individual observations and collective urine samples under daily dietary conditions it was possible that neonates or infants harbouring at least one non-inactive-allele of the FMO3 gene could have developmental FMO3 metabolic capacity in childhood. CONCLUSIONS Developmental variations in functional metabolic capacity of FMO3 in childhood were shown both on the basis of in vivo phenotyping tests and in in vitro liver microsomal determinations. © 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.


Article on FMO3
Article on TMAU

0 comments:

Post a Comment